These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6314889)

  • 1. Penetration of sulbactam and ampicillin into peritoneal fluid.
    Wise R; Donovan IA; Andrews JM; Drumm J; Bennett S
    Antimicrob Agents Chemother; 1983 Aug; 24(2):290-2. PubMed ID: 6314889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration of sulbactam-ampicillin and clavulanic acid-amoxicillin into the pelvic peritoneum.
    Houang ET; Colley N; Chapman M
    Antimicrob Agents Chemother; 1985 Jul; 28(1):165-6. PubMed ID: 2994556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.
    Brown RM; Wise R; Andrews JM; Hancox J
    Antimicrob Agents Chemother; 1982 Apr; 21(4):565-7. PubMed ID: 6282211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of sulbactam/ampicillin in humans: a review.
    Foulds G
    Rev Infect Dis; 1986; 8 Suppl 5():S503-11. PubMed ID: 3025997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
    Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J
    Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
    Campoli-Richards DM; Brogden RN
    Drugs; 1987 Jun; 33(6):577-609. PubMed ID: 3038500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biliary pharmacokinetics of sulbactam plus ampicillin in humans.
    Morris DL; Ubhi CS; Robertson CS; Brammer KW
    Rev Infect Dis; 1986; 8 Suppl 5():S589-92. PubMed ID: 3026008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulbactam: biochemical factors involved in its synergy with ampicillin.
    Labia R; Morand A; Lelievre V; Mattioni D; Kazmierczak A
    Rev Infect Dis; 1986; 8 Suppl 5():S496-502. PubMed ID: 3025996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ampicillin plus sulbactam on bowel flora in patients undergoing colorectal surgery.
    Kager L; Liljeqvist L; Malmborg AS; Nord CE; Pieper R
    Antimicrob Agents Chemother; 1982 Aug; 22(2):208-12. PubMed ID: 6100422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration of sulbactam and ampicillin in serum and the myometrium.
    Schwiersch U; Lang N; Wildfeuer DA
    Drugs; 1986; 31 Suppl 2():26-8. PubMed ID: 3013570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The parenteral kinetics of ampicillin/sulbactam in man.
    Foulds G; Knirsch AK; Stankewich JP; Weidler DR
    Int J Clin Pharmacol Res; 1985; 5(2):79-86. PubMed ID: 2991150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
    Aronoff SC; Jacobs MR; Johenning S; Yamabe S
    Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.
    Wexler HM; Harris B; Carter WT; Finegold SM
    Antimicrob Agents Chemother; 1985 May; 27(5):876-8. PubMed ID: 2990330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis.
    Sorg TB; Cynamon MH
    J Antimicrob Chemother; 1987 Jan; 19(1):59-64. PubMed ID: 3030999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
    Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
    Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial activity of ampicillin alone and in combination with sulbactam correlated with beta-lactamase production.
    Chao HP; Ho SW; Luh KT; Hsieh WC
    Taiwan Yi Xue Hui Za Zhi; 1987 Mar; 86(3):241-7. PubMed ID: 3037003
    [No Abstract]   [Full Text] [Related]  

  • 17. In-vitro evaluation of sulbactam, a penicillanic acid sulphone with beta-lactamase inhibitory properties.
    Greenwood D; Eley A
    J Antimicrob Chemother; 1982 Aug; 10(2):117-23. PubMed ID: 6288651
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro activity of YTR 830.
    Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
    J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro bactericidal activity of sulbactam plus ampicillin against methicillin-resistant Staphylococcus aureus.
    Kazmierczak A; Duez JM; Pechinot A; Nordmann P; Labia R
    Rev Infect Dis; 1986; 8 Suppl 5():S549-54. PubMed ID: 3026003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of sultamicillin in mice, rats, and dogs.
    English AR; Girard D; Haskell SL
    Antimicrob Agents Chemother; 1984 May; 25(5):599-602. PubMed ID: 6329091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.